Batu Biologics, a San Diego, CA-based immuno-oncology company, completed its $1m seed round of funding.
Private and angel investors made the investment.
The company intends to use the funds to advance its lead program ValloVax.
Founded in 2013 and led by Samuel C. Wagner, President and CEO, and Alan Lewis, Chairman, Batu Biologics is developing its lead program ValloVax, a polyvalent cancer vaccine that stimulates an immune response against the tumor-associated blood vessels, seeking to cut off the blood supply required for sustainable tumor growth.
In preclinical testing, ValloVax was shown to inhibit new blood vessel formation in melanoma, breast and lung cancer mouse models.